MAP2K7 and hepatocellular carcinoma: Furthermore, the co-delivery of CXCR4-targeted NPs with MEK inhibitor and sorafenib to HCC can increase the feasibility of dual RAF/MEK inhibition to overcome sorafenib treatment evasion in HCC (Chen et al., 2017).